Cascade Bio lands $6M to accelerate the shift from petrochemicals to biomanufacturing

In Colorado, Cascade Bio has secured $6M to accelerate the shift from petrochemicals to biomanufacturing. The funding includes a $2.8M seed round led by Endurance28 with participation from Stray Dog Capital, 1Flourish, Range Ventures, 10VC, and Amplify plus $3.2M in nondilutive funding from the U.S. National Science Foundation (NSF) through the Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (NSF CFIRE) initiative and an SBIR Phase II award. With this investment, Cascade will expand delivery of its breakthrough biocatalysts, giving industrial partners higher performing enzymes that cut costs and unlock biobased production.

Cascade’s technology uses cost-effective materials to keep expensive enzymes lasting significantly longer. So far, Cascade has worked on over 30 different enzymes and is 100% successful at improving stability under tough industrial conditions, including for over 20 paying customers. These early collaborations include some of the world’s largest chemical, flavor and fragrance, food ingredient and pharmaceutical companies helping them incorporate more biology into their manufacturing processes.